

116TH CONGRESS
1ST SESSION

H. R. 4553

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 27, 2019

Mr. BRENDAN F. BOYLE of Pennsylvania (for himself, Mr. MARSHALL, Mr. VEASEY, and Mr. FORTENBERRY) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Adding Epidemic Dis-
5 eases to the FDA Priority Review Voucher Program Act”.

1 **SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRI-**
2 **ORITY REVIEW VOUCHER PROGRAM TO EN-**
3 **COURAGE TREATMENTS FOR MIDDLE EAST**
4 **RESPIRATORY SYNDROME, NIPAH, AND RIFT**
5 **VALLEY FEVER.**

6 Section 524(a)(3) of the Federal Food, Drug, and
7 Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

8 (1) by redesignating subparagraph (S) as sub-
9 paragraph (V); and

10 (2) by inserting after subparagraph (R) the fol-
11 lowing:

12 “(S) Middle East respiratory syndrome.

13 “(T) Nipah.

14 “(U) Rift Valley fever.”.

○